Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone833-509-4583
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$14.80 million
Profitability
Miscellaneous
Employees95
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable
Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions
What is Assembly Biosciences' stock symbol?
Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."
How were Assembly Biosciences' earnings last quarter?
Assembly Biosciences Inc (NASDAQ:ASMB) posted its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.93) by $0.03. The biopharmaceutical company earned $4.23 million during the quarter, compared to the consensus estimate of $3.45 million. Assembly Biosciences had a negative net margin of 647.72% and a negative return on equity of 52.83%. View Assembly Biosciences' Earnings History.
When is Assembly Biosciences' next earnings date?
What price target have analysts set for ASMB?
4 brokerages have issued 1-year price objectives for Assembly Biosciences' stock. Their forecasts range from $20.00 to $74.00. On average, they anticipate Assembly Biosciences' share price to reach $41.33 in the next twelve months. This suggests a possible upside of 211.0% from the stock's current price. View Analyst Price Targets for Assembly Biosciences.
What is the consensus analysts' recommendation for Assembly Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Assembly Biosciences.
What are Wall Street analysts saying about Assembly Biosciences stock?
Here are some recent quotes from research analysts about Assembly Biosciences stock:
- 1. According to Zacks Investment Research, "Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. " (11/12/2019)
- 2. Chardan Capital analysts commented, "We are also encouraged by the initiation of the phase Ib clinical trial (NCT03923478) for ABI-M201, Assembly’s rationally-designed consortium live biotherapeutic product for UC. We broadly favor this approach to microbiome medicines (MMs) development. Assembly reported $173.8 mm in cash and cash equivalents, providing a runway into 2021." (8/7/2019)
Has Assembly Biosciences been receiving favorable news coverage?
News coverage about ASMB stock has trended somewhat negative on Wednesday, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Assembly Biosciences earned a coverage optimism score of -1.6 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Assembly Biosciences.
Are investors shorting Assembly Biosciences?
Assembly Biosciences saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 2,290,000 shares, an increase of 477.3% from the September 30th total of 396,700 shares. Based on an average trading volume of 548,000 shares, the days-to-cover ratio is presently 4.2 days. Currently, 10.1% of the company's stock are sold short. View Assembly Biosciences' Current Options Chain.
Who are some of Assembly Biosciences' key competitors?
Some companies that are related to Assembly Biosciences include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).
What other stocks do shareholders of Assembly Biosciences own?
Who are Assembly Biosciences' key executives?
Assembly Biosciences' management team includes the folowing people:
- Mr. Derek A. Small, Co-Founder, Pres, CEO & Director (Age 43)
- Dr. Uri A. Lopatin, Co-Founder, Chief Medical Officer and VP of R&D (Age 47)
- Dr. Richard J. Colonno, Exec. VP & Chief Scientific Officer of Virology Operations (Age 69)
- Mr. Thomas E. Rollins, Exec. Officer (Age 63)
- Mr. David J. Barrett CPA, Consultant (Age 43)
Who are Assembly Biosciences' major shareholders?
Assembly Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Emerald Advisers LLC (1.70%), Emerald Mutual Fund Advisers Trust (1.61%), Russell Investments Group Ltd. (0.23%), Assenagon Asset Management S.A. (0.21%), Alps Advisors Inc. (0.20%) and Valeo Financial Advisors LLC (0.14%). Company insiders that own Assembly Biosciences stock include Derek A Small, Uri A Lopatin and William R Ringo. View Institutional Ownership Trends for Assembly Biosciences.
Which institutional investors are selling Assembly Biosciences stock?
ASMB stock was sold by a variety of institutional investors in the last quarter, including Valeo Financial Advisors LLC, Assenagon Asset Management S.A., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust and Alps Advisors Inc.. View Insider Buying and Selling for Assembly Biosciences.
Which institutional investors are buying Assembly Biosciences stock?
How do I buy shares of Assembly Biosciences?
Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Assembly Biosciences' stock price today?
One share of ASMB stock can currently be purchased for approximately $13.29.
How big of a company is Assembly Biosciences?
Assembly Biosciences has a market capitalization of $346.16 million and generates $14.80 million in revenue each year. The biopharmaceutical company earns $-90,750,000.00 in net income (profit) each year or ($3.98) on an earnings per share basis. Assembly Biosciences employs 95 workers across the globe.View Additional Information About Assembly Biosciences.
What is Assembly Biosciences' official website?
How can I contact Assembly Biosciences?
Assembly Biosciences' mailing address is 11711 NORTH MERIDIAN STREET SUITE 310, CARMEL IN, 46032. The biopharmaceutical company can be reached via phone at 833-509-4583 or via email at [email protected]
MarketBeat Community Rating for Assembly Biosciences (NASDAQ ASMB)
MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe ASMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASMB will underperform the S&P 500 over the long term. You may vote once every thirty days.
